Literature DB >> 16463407

Glucocorticoid use, other associated factors, and the risk of tuberculosis.

Susan S Jick1, Eric S Lieberman, Mahboob U Rahman, Hyon K Choi.   

Abstract

OBJECTIVE: To evaluate the association of glucocorticoids and other purported risk factors with the development of tuberculosis.
METHODS: We conducted a case-control study of tuberculosis cases identified during 1990-2001 using the General Practice Research Database in the United Kingdom. Cases were patients with a first time diagnosis of tuberculosis accompanied by at least 6 months of treatment with at least 3 different tuberculosis medications. Up to 4 controls were matched to each case on age, sex, the practice attended by the case, index date, and amount of prior computerized records.
RESULTS: The study encompassed 497 new cases of tuberculosis and 1,966 controls derived from 16,629,041 person-years at risk (n = 2,757,084 persons). The adjusted odds ratio (OR) of tuberculosis for current use of a glucocorticoid compared with no use was 4.9 (95% confidence interval [95% CI] 2.9-8.3). The adjusted ORs for use of <15 mg and > or =15 mg of prednisone or its equivalent daily dose were 2.8 (95% CI 1.0-7.9) and 7.7 (95% CI 2.8-21.4), respectively. Adjusted ORs of tuberculosis were 2.8 for patients with a body mass index (BMI) <20 compared with normal BMI; 1.6 for current smokers compared with nonsmokers; and 3.8, 3.2, 2.0, and 1.4 for those with history of diabetes, emphysema, bronchitis, and asthma, respectively, compared with those without such history (all P values <0.05).
CONCLUSION: These results indicate that patients treated with glucocorticoids have an increased risk of developing tuberculosis, independent of other risk factors. Low adiposity, diabetes, current smoking, and obstructive pulmonary disorders are also important independent risk factors for tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16463407     DOI: 10.1002/art.21705

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  120 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

2.  Trends in long-term glucocorticoid use and risk of 5-year mortality: a historical cohort study in South Korea.

Authors:  Tak Kyu Oh; In-Ae Song
Journal:  Endocrine       Date:  2020-06-16       Impact factor: 3.633

3.  Factors associated with active tuberculosis in Colombian patients with systemic lupus erythematosus: a case-control study.

Authors:  Luis Alonso González-Naranjo; Jaime Alberto Coral-Enríquez; Mauricio Restrepo-Escobar; Carlos Horacio Muñoz-Vahos; Daniel Jaramillo-Arroyave; Adriana Lucía Vanegas-García; Ruth Eraso; Gloria Vásquez; Fabián Jaimes
Journal:  Clin Rheumatol       Date:  2020-06-11       Impact factor: 2.980

Review 4.  Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.

Authors:  Kevin L Winthrop; Michael Iseman
Journal:  Nat Rev Rheumatol       Date:  2013-06-25       Impact factor: 20.543

5.  Tuberculosis infection in primary Sjögren's syndrome: a nationwide population-based study.

Authors:  Yu-Sheng Chang; Chia-Jen Liu; Shou-Ming Ou; Yu-Wen Hu; Tzeng-Ji Chen; Hui-Ting Lee; Chi-Ching Chang; Chung-Tei Chou
Journal:  Clin Rheumatol       Date:  2013-10-30       Impact factor: 2.980

Review 6.  Tuberculosis and diabetes mellitus: convergence of two epidemics.

Authors:  Kelly E Dooley; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

7.  The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis.

Authors:  Léanie Kleynhans; Nelita Du Plessis; Nasiema Allie; Muazzam Jacobs; Martin Kidd; Paul D van Helden; Gerhard Walzl; Katharina Ronacher
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

8.  Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis.

Authors:  Songshi Ni; Zhenxue Fu; Jing Zhao; Hua Liu
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

Review 9.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

Review 10.  Infection Risk and Safety of Corticosteroid Use.

Authors:  Jameel Youssef; Shannon A Novosad; Kevin L Winthrop
Journal:  Rheum Dis Clin North Am       Date:  2015-10-24       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.